Rozibafusp Alfa

DRUG2 trials

Sponsors

Amgen

Conditions

Rheumatoid ArthritisSystemic Lupus Erythematosus (SLE)

Phase 1

Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis

CompletedNCT03156023

AmgenRheumatoid Arthritis

Start: 2017-08-14End: 2020-06-12Updated: 2024-05-14

Phase 2

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

CompletedNCT04058028

AmgenSystemic Lupus Erythematosus (SLE)

Start: 2020-02-19End: 2023-07-25Updated: 2024-09-24

Related Papers

ROZIBAFUSP ALFA IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A BAYESIAN ADAPTIVE PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

The Journal of Rheumatology2025-05-20

P132 Design of an adaptive, phase 2, placebo-controlled, dose-ranging study to assess the efficacy and safety of AMG 570 in subjects with active SLE and inadequate response to standard of care therapy

Poster presentations2020-03-013 citations